We are on a path of expansion which is reflected through our acquisition of a manufacturing facility in Gujarat and completion of our biosimilar facility in Chennai. Commercialization of the biosimilar range is expected in Q3 2022. Additionally, we have now opened three new offices in Spain, UAE, and Costa Rica in order to expand our reach and range in the regions.
Our Journey from humble beginnings
to our proud heritage, Our story began in 1968.
1968
Prime Group starts as an API company in Kolkata.
2010
Enters the African Markets. & South East Asian Markets.
2020
Invested in an EU- compliant bio-similar facility. Expanded global footprint to 50 + countries. Established office in Europe to facilitate partnerships within the EU. Enters the Latin & Central American Markets.
2022
Sets up offices in Costa Rica, Spain, UAE & USA
2023
Established a joint venture in Tanzania for business development and marketing in East Africa. Invested in an EU-compliant greenfield facility. Attained control of an Algerian company with two manufacturing plants
2024
Successful clinical trials for two bio-similar products. Initiated the setup of a diagnostic chain in Tanzania. Commenced the filing process for products in the EU. Triggered EMA audit for OSD and Bio-similar Facilities.
Moving Forward
Prime Pharmaceuticals Pvt. Ltd
B327/328, 3rd Floor,
Chintamani Plaza,
Andheri Kurla Road,
Andheri (East),
Mumbai 400099, INDIA.